financetom
Business
financetom
/
Business
/
BRIEF-Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases
Nov 8, 2024 3:40 AM

Nov 8 (Reuters) - Allovir Inc ( ALVR ):

* ALLOVIR AND KALARIS THERAPEUTICS ANNOUNCE AGREEMENT FOR

TRANSFORMATIONAL MERGER TO CREATE COMPANY FOCUSED ON DISEASES OF

THE RETINA

* ALLOVIR INC ( ALVR ) - TO ACQUIRE 100% OF KALARIS EQUITY INTEREST

* ALLOVIR INC ( ALVR ) - STOCKHOLDERS TO OWN 25.05% OF COMBINED

COMPANY

POST-MERGER

* ALLOVIR INC ( ALVR ) - COMBINED COMPANY TO BE LED BY KALARIS CEO

ANDREW

OXTOBY

* ALLOVIR INC ( ALVR ) - COMBINED COMPANY TO OPERATE AS KALARIS

THERAPEUTICS, INC. AND TRADE AS KLRS

* ALLOVIR INC ( ALVR ) - TH103 PHASE 1 CLINICAL TRIAL DATA EXPECTED

IN Q3

2025

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved